Stockscreener 앱 받기
915.30
0.50%
-4.64
시장 영업 전:
903.41
-11.89
-1.30%
전일 마감가:
$919.94
열려 있는:
$914.15
하루 거래량:
243.70K
Relative Volume:
0.72
시가총액:
$56.92B
수익:
$4.16B
순이익/손실:
$1.29B
주가수익비율:
46.74
EPS:
19.5837
순현금흐름:
$734.26M
1주 성능:
+0.64%
1개월 성능:
+3.73%
6개월 성능:
+15.05%
1년 성능:
+69.93%
1일 변동 폭
$906.23
$920.30
1주일 범위
$906.23
$953.58
52주 변동 폭
$538.91
$953.58
알제넥스 NV ADR Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
915.30 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-12-18 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 재개 | Truist | Buy |
| 2025-09-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2025-01-17 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-11-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
VCRE|Vicore Pharma Holding AB ADR|Price:14.124|Chg%:-0.901 - TradingKey
RBC Capital Adjusts argenx SE ADR Price Target to $945 From $890, Maintains Outperform Rating - marketscreener.com
Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point - Investor's Business Daily
Argenx, stock of the day, eyes buy point amid triple-digit growth - MSN
Argenx Fends Off First-Quarter Seasonality, But Shares Defy Analysts' Bullish Views - Investor's Business Daily
Argenx stock holds the focus on its global immunology franchise. - Ad-hoc-news.de
ARGXArgen X SE ADR Options - Finviz
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx stock hits all-time high at 934.69 USD - Investing.com
ARGX Stock Price, Quote & Chart - ChartMill
BofA raises argenx stock price target to $1,088 on myositis data - Investing.com
Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth - Investor's Business Daily
A2H9WD Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
argenx SE Sponsored ADR Actuals & Estimates (NASDAQ:ARGX) - TradingView
H.C. Wainwright reiterates argenx stock rating on myositis trial update By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates argenx stock rating on myositis trial update - Investing.com
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy? - Investor's Business Daily
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity By Investing.com - Investing.com South Africa
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data By Investing.com - Investing.com Australia
Argenx stock price target held at $1,014 by Oppenheimer on myositis strategy - Investing.com Nigeria
Argenx stock falls after myositis drug trial update - Investing.com
Biotech breakout: iShares Biotechnology ETF hits all-time high - MSN
Form 6K argenx NV ADR For: 23 June - Investing.com UK
Form 6K argenx NV ADR For: 23 June By Investing.com - Investing.com Nigeria
argenx to Host Autoimmune Myositis R&D Webinar - GlobeNewswire Inc.
Novabridge Biosciences ADR (NBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galapagos ADR Representing Ord Shs (LKFT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Argenx SE Stock (NL0010832176): Analyst price target move puts biotech in focus - AD HOC NEWS
European ADRs Rose In US Trading As Biotech Led - Finimize
European Equities Traded in US as ADRs Rise in Thursday Trading - Moomoo
Sanofi Scraps Its Argenx Rival; Why Another Biotech Took The Hit - Investor's Business Daily
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know - TradingView
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
William O'Neil Initiates Argenx at Buy - Moomoo
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference - Barchart.com
H.C. Wainwright reiterates Buy on argenx stock, $940 target - Investing.com UK
H.C. Wainwright reiterates Buy on argenx stock, $940 target By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 3 June By Investing.com - Investing.com India
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.59%
자본화:
|
볼륨(24시간):